While the immediate unmet patient need for superior bispecific antibody therapies is enormous, there is also a future opportunity for antibody products that bind to more than two antigens. Merus addresses both areas by developing Biclonics™ and Oligoclonics® product candidates against targets in oncology.
Lead candidates are selected for synergistic effects in in vitro assays and in vivo models of human disease. After production of Biclonics™ and Oligoclonics® antibodies in a single clonal cell, superiority over single monoclonal antibody therapies is established.
In Merus´ current oncology programs, targets include combinations of surface molecules expressed on tumor cells and/or effector cells. Merus has programs in both solid and hematological tumors. Merus plans to take the most promising oncology product candidates into pre-clinical development and clinical testing to provide proof of superior clinical efficacy.
Merus Pipeline
